Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes Aristoteles GiagounidisGhulam J. MuftiKyle J. MacBeth Review Article Open access 10 September 2013 Pages: 1 - 11
Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Sabine MoussetDieter BuchheidtAngelika Böhme Original Article Open access 12 September 2013 Pages: 13 - 32
The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea Jin Seok KimJune-Won CheongYoo Hong Min Original Article 27 June 2013 Pages: 33 - 42
Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia David Martínez-CuadrónPau MontesinosMiguel A. Sanz Original Article 01 October 2013 Pages: 43 - 46
Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML) Bernard TawfikSarunas SliesoraitisTimothy Pardee Original Article 23 October 2013 Pages: 47 - 55
Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis Sigrid Machherndl-SpandlW. SegaO. Krieger Original Article 17 November 2013 Pages: 57 - 64
Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow Judith NeukirchenUwe PlatzbeckerUlrich Germing Original Article 10 August 2013 Pages: 65 - 69
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV Lida KalmantiSusanne SausseleSchweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) Original Article Open access 27 October 2013 Pages: 71 - 80
The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis Philipp ErbenJuliana SchwaabAndreas Reiter Original Article 27 November 2013 Pages: 81 - 88
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma James R. BerensonJames D. HilgerRobert Vescio Review Article 18 October 2013 Pages: 89 - 98
DCEP for relapsed or refractory multiple myeloma after therapy with novel agents Silvia ParkSu Jin LeeKihyun Kim Original Article 16 November 2013 Pages: 99 - 105
Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma Natalia TovarCarlos Fernández de LarreaJoan Bladé Original Article 12 November 2013 Pages: 107 - 111
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea—experience from 110 patients Kihyun KimSeok Jin KimKorean Multiple Myeloma Working Party (KMMWP) Original Article 12 September 2013 Pages: 113 - 121
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes Lucia PantaniElena ZamagniMichele Cavo Original Article 18 July 2013 Pages: 123 - 128
“Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group Eirini KatodritouChrysanthi VadikoliaEvangelos Terpos Original Article 28 July 2013 Pages: 129 - 139
Multiple myeloma: a descriptive study of 217 Egyptian patients Noha M. El HusseinyNeemat KasemMervat W. Mattar Original Article 28 July 2013 Pages: 141 - 145
Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17 years’ experience in a single centre Sinziana Radesi-SarghiFlavie ArbionEmmanuel Gyan Original Article 14 November 2013 Pages: 147 - 156
Increased risk of chronic lymphocytic leukaemia among cancer survivors in the Netherlands: increased detection, causal factors or both? E. C. van den BroekL. LiuI. Soerjomataram Original Article 25 October 2013 Pages: 157 - 162
EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations Massimiliano BonifacioGianni BinottoGruppo Triveneto LMC Letter to the Editor 29 November 2013 Pages: 163 - 164
No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year "real-life" evaluation Hartmut BertzKathrin DrognitzMichael Lübbert Letter to the Editor 15 August 2013 Pages: 165 - 167
Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies Yasuyo OhyamaTakahiro KumodeYasuhiro Maeda Letter to the Editor 24 April 2013 Pages: 169 - 171
An atypical manifestation of acquired von Willebrand syndrome (AVWS) associated with systemic lupus erythematosus (SLE) Priyanka KasatkarKanjaksha GhoshShrimati Shetty Letter to the Editor 27 April 2013 Pages: 173 - 175
Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH) Igor AurerSandra Bašić-KindaJosip Joachim Grah Letter to the Editor 02 May 2013 Pages: 177 - 178
MtDNA depletion and deletions may also have a role in myelodysplastic syndrome Tuncer CayciBulent KurtEmin Ozgur Akgul Letter to the Editor 09 May 2013 Pages: 179 - 179
